Biotalys NV
Biotalys NV is a biotechnology company focused on the development and commercialization of phytase enzymes for the animal feed industry, primarily in the Food & Beverages sector.
Business. Biotalys NV (BTLS.BR) is a food and beverage company operating within the Fishing & Farming industry. The firm is headquartered in Belgium and is primarily listed on the Euronext Brussels exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Biotalys NV (BTLS.BR) is a food and beverage company operating within the Fishing & Farming industry. The firm is headquartered in Belgium and is primarily listed on the Euronext Brussels exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Biotalys has a fully diluted share count of 37.5 million shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible instruments. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to compare with industry_config preferred metrics or cohort medians. Without disclosed revenue, EBITDA, or net income figures, a direct assessment of profitability is not possible.
Biotalys operates in a single business segment focused on phytase enzymes for animal feed, with no geographic revenue breakdown provided. This lack of segmentation data limits the ability to assess geographic exposure or revenue concentration.
The company's growth trajectory is unclear due to the absence of historical revenue data and forward-looking guidance. Analysts have provided a uniform price target of 6.00 EUR, with a mean recommendation of 1.50 (leaning toward strong buy), but no numeric deltas or outlook data are available to quantify growth expectations.
The risk assessment indicates low dilution risk, but liquidity risk could not be evaluated due to missing balance-sheet data. No specific risk factors or dilution sources are disclosed in the available source documents.
Recent events and filings are not detailed in the available data, and no transcripts or material disclosures are provided to inform recent company developments.
- Biotalys has no immediate dilution risk as basic and diluted shares are equal.
- Analysts have assigned a consistent price target of 6.00 EUR, with a strong buy bias.
- The company's liquidity risk remains unassessed due to missing balance-sheet inputs.
- No revenue or profitability data is available to assess performance against industry benchmarks.
- The company operates in a single business segment with no geographic segmentation provided.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income +35,4% YoY; Net income +35,7% YoY.
- ▍Operating income +35,4% YoY
- ▍Net income +35,7% YoY
- ▍Free cash flow +40,1% YoY
Operating income +7,3% YoY; Net income +9,8% YoY.
- ▍Operating income +7,3% YoY
- ▍Net income +9,8% YoY
- ▍Free cash flow +12,3% YoY
Operating income −24,6% YoY; Net income −34,3% YoY.
- ▍Operating income −24,6% YoY
- ▍Net income −34,3% YoY
- ▍Free cash flow −30,2% YoY
Operating income −36,2% YoY; Net income −57,5% YoY.
- ▍Operating income −36,2% YoY
- ▍Net income −57,5% YoY
- ▍Free cash flow −23,1% YoY
Operating income -€13.3M.
- ▍Operating income -€13.3M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,28 |
| Revenue | —no estimate | —no estimate | 6,5M EUR |
| Operating income | —no estimate | —no estimate | -11,5M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Biotalys NV Market data — financials · 2026-05-27
- Biotalys NV Market data — analyst estimates · 2026-05-27